193 related articles for article (PubMed ID: 31394872)
1. Detection of
Rodriguez BJ; Córdoba GD; Aranda AG; Álvarez M; Vicioso L; Pérez CL; Hernando C; Bermejo B; Parreño AJ; Lluch A; Ryder MB; Jones FS; Fredebohm J; Holtrup F; Queipo-Ortuño MI; Alba E
J Clin Med; 2019 Aug; 8(8):. PubMed ID: 31394872
[TBL] [Abstract][Full Text] [Related]
2. PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study.
Tzanikou E; Markou A; Politaki E; Koutsopoulos A; Psyrri A; Mavroudis D; Georgoulias V; Lianidou E
Mol Oncol; 2019 Dec; 13(12):2515-2530. PubMed ID: 31254443
[TBL] [Abstract][Full Text] [Related]
3. Detection of TP53/PIK3CA Mutations in Cell-Free Plasma DNA From Metastatic Breast Cancer Patients Using Next Generation Sequencing.
Nakauchi C; Kagara N; Shimazu K; Shimomura A; Naoi Y; Shimoda M; Kim SJ; Noguchi S
Clin Breast Cancer; 2016 Oct; 16(5):418-423. PubMed ID: 27265061
[TBL] [Abstract][Full Text] [Related]
4. Molecular profiles and circulating tumor-DNA detected in Chinese early stage breast cancer.
Lan J; Zhou YH; Zhang MX; Chen DQ; Wu MY; Yu ZY
Gland Surg; 2022 Feb; 11(2):319-329. PubMed ID: 35284312
[TBL] [Abstract][Full Text] [Related]
5. Targeted next generation sequencing of circulating tumor DNA provides prognostic information for management in breast cancer patients.
Shim H; Kwon MJ; Park IH; Kim MK; Cho EH; Lee J; Lee ST; Sim SH; Lee KS; Kim YH; Kim SK; Lee ES; Kong SY
Ann Transl Med; 2022 Jan; 10(2):28. PubMed ID: 35282050
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J
Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823
[TBL] [Abstract][Full Text] [Related]
7. Correlation between circulating cell-free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA-mutated metastatic breast cancer.
Kodahl AR; Ehmsen S; Pallisgaard N; Jylling AMB; Jensen JD; Laenkholm AV; Knoop AS; Ditzel HJ
Mol Oncol; 2018 Jun; 12(6):925-935. PubMed ID: 29689598
[TBL] [Abstract][Full Text] [Related]
8. Design of a Targeted Sequencing Assay to Detect Rare Mutations in Circulating Tumor DNA.
Chen J; Chen J; He F; Huang Y; Lu S; Fan H; Wang M; Xu R
Genet Test Mol Biomarkers; 2019 Apr; 23(4):264-269. PubMed ID: 30986100
[TBL] [Abstract][Full Text] [Related]
9. Parallel Analyses of Somatic Mutations in Plasma Circulating Tumor DNA (ctDNA) and Matched Tumor Tissues in Early-Stage Breast Cancer.
Zhang X; Zhao W; Wei W; You Z; Ou X; Sun M; Yin Y; Tang X; Zhao Z; Hu C; Liu F; Deng J; Mao L; Zhou D; Ren Y; Li X; Zhang S; Liu C; Geng J; Yao G; Song B; Liu Y; Li D; Jiang Y; Chen Y; Zhao Y; Yu S; Pang D
Clin Cancer Res; 2019 Nov; 25(21):6546-6553. PubMed ID: 31350313
[TBL] [Abstract][Full Text] [Related]
10. Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer.
Zhang B; Niu X; Zhang Q; Wang C; Liu B; Yue D; Li C; Giaccone G; Li S; Gao L; Zhang H; Wang J; Yang H; Wu R; Ni P; Wang C; Ye M; Liu W
Lung Cancer; 2019 Aug; 134():108-116. PubMed ID: 31319968
[TBL] [Abstract][Full Text] [Related]
11. Correlation of genomic alterations between tumor tissue and circulating tumor DNA by next-generation sequencing.
Chang YS; Fang HY; Hung YC; Ke TW; Chang CM; Liu TY; Chen YC; Chao DS; Huang HY; Chang JG
J Cancer Res Clin Oncol; 2018 Nov; 144(11):2167-2175. PubMed ID: 30203147
[TBL] [Abstract][Full Text] [Related]
12. Mutation profile differences in younger and older patients with advanced breast cancer using circulating tumor DNA (ctDNA).
Clifton K; Luo J; Tao Y; Saam J; Rich T; Roshal A; Frith A; Rigden C; Ademuyiwa F; Weilbaecher K; Hernandez-Aya L; Peterson LL; Bagegni N; Suresh R; Bose R; Opyrchal M; Wildes TM; Ma C
Breast Cancer Res Treat; 2021 Feb; 185(3):639-646. PubMed ID: 33219484
[TBL] [Abstract][Full Text] [Related]
13. Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients.
Madic J; Kiialainen A; Bidard FC; Birzele F; Ramey G; Leroy Q; Rio Frio T; Vaucher I; Raynal V; Bernard V; Lermine A; Clausen I; Giroud N; Schmucki R; Milder M; Horn C; Spleiss O; Lantz O; Stern MH; Pierga JY; Weisser M; Lebofsky R
Int J Cancer; 2015 May; 136(9):2158-65. PubMed ID: 25307450
[TBL] [Abstract][Full Text] [Related]
14. Detection of oncogenic mutations in paired circulating tumor DNA and circulating tumor cells in patients with hepatocellular carcinoma.
Ge Z; Helmijr JCA; Jansen MPHM; Boor PPC; Noordam L; Peppelenbosch M; Kwekkeboom J; Kraan J; Sprengers D
Transl Oncol; 2021 Jul; 14(7):101073. PubMed ID: 33915518
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive Gene Mutation Profiling of Circulating Tumor DNA in Ovarian Cancer: Its Pathological and Prognostic Impact.
Noguchi T; Iwahashi N; Sakai K; Matsuda K; Matsukawa H; Toujima S; Nishio K; Ino K
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33207545
[TBL] [Abstract][Full Text] [Related]
16. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
Li Y; Zhang FS; Guo L; Ying JM
Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
[No Abstract] [Full Text] [Related]
17. [Current situation and prospect of breast cancer liquid biopsy].
Zhou B; Xin L; Xu L; Ye JM; Liu YH
Zhonghua Wai Ke Za Zhi; 2018 Feb; 56(2):106-109. PubMed ID: 29397622
[TBL] [Abstract][Full Text] [Related]
18. Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages.
Yang M; Topaloglu U; Petty WJ; Pagni M; Foley KL; Grant SC; Robinson M; Bitting RL; Thomas A; Alistar AT; Desnoyers RJ; Goodman M; Albright C; Porosnicu M; Vatca M; Qasem SA; DeYoung B; Kytola V; Nykter M; Chen K; Levine EA; Staren ED; D'Agostino RB; Petro RM; Blackstock W; Powell BL; Abraham E; Pasche B; Zhang W
J Hematol Oncol; 2017 May; 10(1):100. PubMed ID: 28472989
[TBL] [Abstract][Full Text] [Related]
19.
Arimura A; Sakai K; Kaneshiro K; Morisaki T; Hayashi S; Mizoguchi K; Yamada M; Kai M; Ono M; Nishio K; Nakamura M; Kubo M
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539518
[TBL] [Abstract][Full Text] [Related]
20. Clearance of ctDNA in triple-negative and HER2-positive breast cancer patients during neoadjuvant treatment is correlated with pathologic complete response.
Ciriaco N; Zamora E; Escrivá-de-Romaní S; Miranda Gómez I; Jiménez Flores J; Saura C; Sloane H; Starus A; Fredebohm J; Georgieva L; Speight G; Jones F; Ramón Y Cajal S; Espinosa-Bravo M; Peg V
Ther Adv Med Oncol; 2022; 14():17588359221139601. PubMed ID: 36479470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]